- May 6, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Idamycin PFS
Synonyms :
Class :
Antineoplastic agents: antibiotics (topoisomerase II inhibitor)
Dosage Forms & Strengths
Injectable solution
5mg/5ml
10mg/10ml
20mg/20ml
acute lymphoblastic leukemia(All)
12
mg/m^2
Intravenous (IV)
per day IV for 3 days in combination with cytarabine
12
mg/m^2
Intravenous (IV)
once a day
on 2, 4, 6, and 8 days in combination with tretinoin
Dosage Forms & Strengths
Injectable solution
5mg/5ml
10mg/10ml
20mg/20ml
acute lymphoblastic leukemia(All)
5
mg/m^2
per day IV for 3 days in combination with cytarabine
5
mg/m^2
Intravenous (IV)
once a day
for 4 days in combination with cytarabine, etoposide, thioguanine, and dexamethasone
Dosage Forms & Strengths
Injectable solution
5mg/5ml
10mg/10ml
20mg/20ml
acute lymphoblastic leukemia(All)
For < 60 years: 12 mg/m2 per day IV on days 2, 4, 6, and 8 in combination with tretinoin
For age 61 to 70: 9 mg/m2 per day IV on days 2, 4, 6, and 8 in combination with tretinoin
For age 61 to 70: 9 mg/m2 per day IV on days 2, 4, 6, and 8 in combination with tretinoin
For age >70: 6 mg/m2 per day IV on days 2, 4, 6, and 8 in combination with tretinoin
may enhance the immunosuppressive effect of immunosuppressants
may diminish therapeutic effects of the vaccine
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
may increase the serum concentration and adverse effects of idarubicin by inhibiting BCRP
anthracyclines may decrease the serum concentration of digoxin
increase serum level of idarubicin by P-glycoprotein efflux transporter
increases serum level of idarubicin by P-glycoprotein efflux transporter
influenza virus vaccine trivalent
decreases therapeutic effects of influenza vaccine
increase serum level of idarubicin by P-glycoprotein efflux transporter
interaction increases toxic effects of idarubicin
interaction increases toxic effects of idarubicin
increase serum level of idarubicin by P-glycoprotein efflux transporter
increases serum level of idarubicin by P-glycoprotein efflux transporter
increases immunosuppressive effects and risk of serious infections
increase myelosuppressive effects by increasing serum concentration of idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the excretion and reduce the effects of idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may enhance immunosuppressive effects of idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase cardiac toxicity risk
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may diminish therapeutic effects of the vaccine
may enhance bone marrow suppression
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
enhance cardiac toxicity
may diminish the therapeutic effects of the vaccine
may enhance immunosuppressive effects of idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
decrease the metabolism of idarubicin and increase serum levels
decrease the metabolism of idarubicin and increase serum levels
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may enhance the risk of serious infections due to increased immunosuppressive effects
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
decrease the metabolism of idarubicin and increase serum levels
decrease the metabolism of idarubicin and increase serum levels, also increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases bone marrow suppression
increases cardiac distress risk
increases immunosuppression
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporteridarub
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may enhance the risk of serious infections due to increased immunosuppressive effects
may enhance the risk of serious infections due to increased immunosuppressive effects
may enhance the adverse effects such as bone marrow suppression
increases the effects of idarubicin by inhibiting BCRP transport
eases the effects of idarubicin by inhibiting BCRP transport
immunosuppressive drugs may reduce the therapeutic effects of pidotimod
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter idaru
may enhance the adverse effects such as bone marrow suppression
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases the effects of idarubicin by inhibiting BCRP transport
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases the effects of idarubicin by inhibiting BCRP transport
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases immunosuppressive effects and increases the risk of serious infection
may diminish the therapeutic effects of sipuleucel-T
increases the effects of idarubicin by inhibiting BCRP transport
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases the effects of idarubicin by inhibiting BCRP transport
increase bone marrow suppression
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
may increase the risk of cardiotoxicity
Frequency defined:
>10%:
ECG abnormality
Ventricular premature contractions
Alopecia
Nausea
Vomiting
Weight loss
Mucositis
Anorexia
Myelosuppression
Pulmonary fibrosis
1% to 10%
Discoloration of sweat
Hyperuricemia
Diarrhea
Gastrointestinal ulcer
Discoloration of saliva
<1%
Anaphylactoid
Cardiac failure
Cardiac arrhythmia
Hepatitis
Increased serum bilirubin
Infertility
Nail banding
Pregnancy: Idarubicin falls under the pregnancy category D. idarubicin can cross the placenta and can cause fetal harm.
Lactation: excretion of idarubicin in breast milk is unknown
Pregnancy category:
Patient information leaflet
Generic Name: Idarubicin
Pronounced: ida-roo-bi-cin
Why do we use idarubicin?
Idarubicin is an anthracycline topoisomerase II inhibitor chemotherapeutic drug. It is used to treat a certain type of leukemia.